Report on Investigational Agent JNJ-89495120 (PIPE-307)

1. Introduction and Overview of JNJ-89495120 (PIPE-307)

1.1. Identification

JNJ-89495120 is an investigational, orally administered small molecule drug.[1] This compound is also prominently known in scientific literature and early development communications as PIPE-307.[1] Additional synonyms used include JNJ 89495120 and JNJ89495120.[6] The consistent use of these identifiers is important for accurately tracking the compound's development progress across different research groups and publications.

JNJ-89495120 (PIPE-307) is classified as a selective M1 muscarinic acetylcholine receptor (M1R) antagonist.[4] The M1R is one of five subtypes of muscarinic acetylcholine receptors (M1-M5), which are G-protein coupled receptors (GPCRs). M1Rs are predominantly expressed within the central nervous system (CNS), particularly in regions like the telencephalon, and are also found in autonomic ganglia. They play a significant role in mediating cholinergic neurotransmission and are implicated in various cognitive functions, including learning, memory, and attention, as well as modulating cellular responses through signaling pathways such as phospholipase C activation and the regulation of intracellular calcium levels.[8] The therapeutic strategy for PIPE-307 centers on its selective antagonism of this specific receptor subtype. For the indication of Relapsing-Remitting Multiple Sclerosis (RRMS), it is being investigated as a potentially first-in-class M1 receptor antagonist with a novel mechanism focused on remyelination.[10]

1.2. Developers and Collaborations